SequelSEC

PALISADE BIO, INC. PALI

Biological Products, (No Diagnostic Substances) · CIK 0001357459 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$500.00K
Fiscal year ended 2026-06-30
Operating income
-$11.70M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

PALISADE BIO, INC. (PALI) reported revenue of $500.00K and net income of -$10.57M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from PALISADE BIO, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

PALISADE BIO, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$500.00K$0$0$0$0$0$0$0$0$0
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$11.70M-$10.75M-$9.98M-$2.92M-$2.84M-$2.31M-$3.38M-$3.59M-$4.21M-$3.67M
Net income-$10.57M-$9.60M-$8.90M-$2.87M-$2.78M-$2.23M-$3.34M-$3.49M-$4.08M-$3.53M
Research & development$6.00M$6.00MUnavailableUnavailableUnavailableUnavailable$0$16.00MUnavailableUnavailable
Weighted-average diluted sharesshares 211.38Mshares 209.66MUnavailableshares 7.47Mshares 4.80Mshares 4.80MUnavailableshares 1.50Mshares 1.23MUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-0.05$-0.05Unavailable$-0.38$-0.58$-0.47Unavailable$-2.32$-3.32$-4.59
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$4.80M$4.35M$3.81M$1.53M$1.17M$1.36M$1.30M$1.46M$1.58M$1.46M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

PALISADE BIO, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$125.17M$132.63M$133.38M$5.23M$5.42M$7.23M$9.82M$8.04M$11.35M$11.28M
Total assets$127.32M$133.32M$134.34M$6.97M$6.67M$8.19M$10.88M$9.34M$12.87M$12.65M
Current assets$127.26M$133.24M$134.22M$6.83M$6.45M$7.89M$10.49M$8.87M$12.31M$12.01M
Total liabilities$5.57M$5.95M$4.96M$3.76M$4.05M$2.86M$3.39M$2.73M$2.92M$2.59M
Current liabilities$5.25M$5.62M$4.64M$3.48M$3.97M$2.78M$3.24M$2.68M$2.84M$2.47M
Total equity incl. NCI$121.75M$127.36M$129.38M$3.21M$2.62M$5.33M$7.49M$6.61M$9.95M$10.06M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$500.00KUnavailable$0Unavailable$0Unavailable$0UnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$1.84M$2.70M$767.00K$1.43M$1.37M$745.00K$1.10M$366.00K$514.00K$459.00K

Cash flow

PALISADE BIO, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$7.60M-$3.89M-$3.14M-$3.55M-$1.82M-$2.33M-$2.38M-$3.13M-$3.50M-$3.18M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$0$0UnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$0$0UnavailableUnavailable
Financing cash flow$147.00K$3.13M$131.33M$3.36M$4.00K-$258.00K$4.16M-$180.00K$3.58M$2.02M
Net change in cash-$7.46M-$757.00K$128.19M-$190.00K-$1.81M-$2.59M$1.78M-$3.31M$77.00K-$1.16M
Stock-based compensation$4.78M$4.30M$3.73M$90.00K$69.00K$69.00K$77.00K$95.00K$362.00K$118.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

PALISADE BIO, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-2339.6%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenue957.0%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio24.26x23.71x28.95x1.96x1.62x2.84x3.24x3.31x4.34x4.87x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-100.0%
Net margin-2114.8%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenue1200.0%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PALI in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-20View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-11View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2023-09-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2023-09-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.